Lumos Pharma Inc Stock Price, News & Analysis

Lumos Pharma (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, announced its participation in virtual investor conferences in December 2020. The company will engage in a fireside chat on November 23 and host one-on-one meetings on December 2 at the Piper Sandler Healthcare Conference. Additionally, Lumos will participate in a panel discussion at the Evercore ISI HealthCONx on December 3, where further one-on-one meetings will occur. The discussions will focus on Lumos' lead candidate, LUM-201, for Pediatric Growth Hormone Deficiency, which is an orally administered alternative to injections.

Lumos Pharma has commenced its Phase 2b OraGrowtH210 Trial to evaluate oral LUM-201 in pediatric growth hormone deficiency (PGHD) patients, anticipating data read-out by mid-2022. The company reported a net income of $1.8 million for Q3 2020, a notable improvement over the $2.7 million loss in Q3 2019. Lumos has secured $34 million from the first tranche of its PRV sale and expects to receive the remaining $26 million in Q1 2021. The firm ended Q3 2020 with $105.6 million in cash, sufficient to fund operations through crucial trial milestones.

AUSTIN, Texas, Oct. 29, 2020 - Lumos Pharma (NASDAQ:LUMO) announced its participation in two upcoming virtual investor conferences in November. The Stifel Healthcare Conference is scheduled for November 16, where management will host a fireside chat from 8:00-8:30AM ET and hold one-on-one meetings. The Jefferies London Healthcare Conference follows on November 17, with a fireside chat from 2:20-2:50PM ET. Live webcasts will be available on the company's website, and presentations will be archived for later viewing.

Lumos Pharma (NASDAQ:LUMO) will report its third quarter 2020 financial results after market close on November 10, 2020. A conference call will be held at 4:30 PM ET to discuss the results and provide updates on corporate activities, including a Q&A session. Investors can access the live audio webcast by dialing in or through the Lumos Pharma website. The company focuses on developing therapeutics for rare diseases, with its lead candidate, LUM-201, aimed at treating Pediatric Growth Hormone Deficiency and holding Orphan Drug Designation in the US and EU.

Lumos Pharma (NASDAQ: LUMO), a biopharmaceutical company focused on rare disease therapeutics, will participate in two virtual investor conferences in September 2020. At the H.C. Wainwright 22nd Annual Global Investment Conference from September 14-16, Lumos will present on September 14 at 4:30 PM ET and host one-on-one meetings. Additionally, at the Cantor Virtual Global Healthcare Conference on September 15-17, they will present on September 17 at 8:40 AM ET. Webcasts of both presentations will be available on their website.

Lumos Pharma has announced the sale of its Priority Review Voucher (PRV) for $100 million, receiving $60 million due to a 60% interest. This non-dilutive funding will enhance its balance sheet as the company prepares for a Phase 2b trial of LUM-201 in Pediatric Growth Hormone Deficiency (PGHD) by year-end 2020. Despite COVID-19 challenges, Lumos remains focused on expanding its rare disease pipeline and maintaining a robust cash position of $72.7 million. The company reported a net loss of $5.4 million for Q2 2020, up from $2.6 million in Q2 2019, with significant increases in R&D and G&A expenses.

Lumos Pharma (NASDAQ:LUMO) will announce its Q2 2020 financial results on August 13, 2020, after market close. A conference call and webcast will follow at 4:30 PM ET for discussing the results and corporate updates, with a Q&A session included. Investors can access the call via this link. Lumos Pharma is focused on developing therapies for rare diseases, with its lead candidate, LUM-201, targeting Pediatric Growth Hormone Deficiency and offering an alternative to daily injections.

Lumos Pharma (NASDAQ: LUMO) announced a definitive agreement to sell its Priority Review Voucher (PRV) to Merck for $60 million. The PRV, valued at $100 million, was granted by the FDA for the ERVEBO® vaccine. This transaction, expected to close after customary conditions, will provide Lumos with non-dilutive capital to expand its pipeline and explore acquisitions. Furthermore, the company plans to initiate its Phase 2b trial for LUM-201, a treatment for Pediatric Growth Hormone Deficiency (PGHD), by the end of 2020. This funding is in addition to their existing cash reserves.

Lumos Pharma (NASDAQ:LUMO) announced its financial results for Q1 2020, revealing a net income of $340,000, a significant improvement from a loss of $2.1 million in Q1 2019. Following the merger with NewLink Genetics, cash reserves increased to $85.8 million, sufficient to support operations through the Phase 2b trial of LUM-201 for Pediatric Growth Hormone Deficiency (PGHD), expected to start by year-end. Despite potential COVID-19 delays, the company aims to expand its pipeline and leverage non-dilutive funding from a priority review voucher.